Germline mutation of HRPT2 in patients with HPT by Mizusawa, Noriko et al.
1 
Genetic analyses in patients with familial isolated hyperparathyroidism 
and hyperparathyroidism-jaw tumor syndrome 
Short Title: Germline mutation of HRPT2 in patients with hyperparathyroidism 
Noriko Mizusawa1, Shinya Uchino5, Takeo Iwata1, Masaru Tsuyuguchi16, Yasuyo Suzuki7, 
Tsunenori Mizukoshi6, Yoshio Yamashita8, Akihiro Sakurai9, Shinichi Suzuki10, Mutsuo 
Beniko11, Hideki Tahara12, Masato Fujisawa13, Nobuyuki Kamata14, Kenji Fujisawa3, Tohru 
Yashiro15, Daisuke Nagao2, Hossain Md. Golam1, Toshiaki Sano4, Shiro Noguchi5, Katsuhiko 
Yoshimoto1 
1Department of Medical Pharmacology, 2Department of Oral and Maxillofacial 
Prosthodontics, 3Department of Oral and Maxillofacial Surgery, and 4Department of Human 
Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, 
Tokushima, Japan  
5Noguchi Thyroid Clinic and Hospital Foundation, Beppu, Japan 
6First Department of Internal Medicine and 7First Department of Surgery, Sapporo Medical 
University School of Medicine, Sapporo, Japan 
8Department of Oral and Maxillofacial Surgery, School of Medicine, Saga University, Saga, 
Japan 
9Department of Preventive Medicine, Shinshu University School of Medicine, Matsumoto, 
Japan 
10Department of Surgery II, Fukushima Medical University School of Medicine, Fukushima, 
Japan 
11Department of Internal Medicine, Kin-ikyo Sapporo Hospital, Sapporo, Japan 
This is the peer reviewed version of the following article: Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai 
A, Suzuki S, Beniko M, Tahara H, Fujisawa M, Kamata N, Fujisawa K, Yashiro T, Nagao D, Golam HM, Sano T, Noguchi S, Yoshimoto K. 
Clin Endocrinol. 2006;65:9-16., which has been published in final form at https://doi.org/10.1111/j.1365-2265.2006.02534.x. 
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
 2 
12Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University 
Graduate School of Medicine, Osaka, Japan 
13Department of Urology, Kawasaki Medical School, Kurashiki, Japan 
14Department of Oral and Maxillofacial Surgery, Graduate School of Biomedical Sciences, 
Hiroshima University, Hiroshima, Japan  
15Department of Surgery, Institute of Basic Medical Sciences, University of Tsukuba, 
Tsukuba, Japan 
16Department of Surgery, Tokushima Municipal Hospital, Tokushima, Japan 
 
Keywords: HPT-JT; HRPT2; FIHP; parathyroid tumor; jaw tumor 
 
Correspondence and reprint requests to: 
Katsuhiko Yoshimoto, M.D., Ph.D., 
Department of Medical Pharmacology, Institute of Health Biosciences,  
The University of Tokushima Graduate School 
3-18-15, Kuramoto-cho, Tokushima City 770-8504, Japan 
Tel:  +81-88-633-9123 







 A subset of familial isolated primary hyperparathyroidism (FIHP) is a variant 
of hyperparathyroidism-jaw tumor syndrome (HPT-JT).   
Aim/Patients and Methods 
 We investigated the involvement of the HRPT2, MEN1, and CASR genes in 
provisional 11 FIHP families and 2 HPT-JT families.  
Results 
 Germline mutations of HRPT2 were found in 2 of 11 FIHP families and 1 of 2 
HPT-JT families.  One FIHP family with parathyroid carcinoma and atypical 
adenomas, and another FIHP family with cystic parathyroid adenoma had 
novel frameshift mutations of 518-521del and 62-66del, respectively.  In a 
patient with HPT-JT, a de novo germline mutation of 39delC was detected.  
Novel somatic HRPT2 mutations of 70-73del and 95-102del were found in 2 of 
5 parathyroid tumors in a family with 518-521del mutation.  Biallelic 
inactivation of HRPT2 by a combination of germline mutation and somatic 
mutation was confirmed in parathyroid tumors.  The finding that 2 families 
diagnosed with FIHP carried HRPT2 mutations suggests that they have occult 
HPT-JT.  In the remaining 10 families, one family had a missense MEN1 
mutation.  No mutations of CASR were detected.   
Conclusion  
 Our results confirm the need to test for HRPT2 in FIHP families, especially in 
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those with parathyroid carcinomas, atypical adenomas, or adenomas with cystic 























  Primary hyperparathyroidism (PHPT) is usually a sporadic disorder, but in 
rare cases, it is part of hereditary endocrine tumor syndromes, namely multiple 
endocrine neoplasia types 1 and 2A (MEN1 and MEN2A), 
hyperparathyroidism-jaw tumor syndrome (HPT-JT), familial hypocalciuric 
hypercalcemia (FHH), or familial isolated hyperparathyroidism (FIHP).   
  MEN1 and MEN2A result from germline mutations of MEN1 and RET, 
respectively. 1  Most cases of FHH result from a mutation of the 
calcium-sensing receptor gene (CASR) . 2  
  HPT-JT with an autosomal dominant mode of inheritance is predisposed to 
parathyroid tumors and jaw tumors.  A relatively high frequency (15%) of 
parathyroid carcinoma was reported in patients with HPT-JT. 3  Furthermore, 
30% of patients develop ossifying or cementifying fibroma of the mandible or 
maxilla.  Renal lesions such as cysts and solid tumors, and uterine tumors 
were described.4  The gene causing HPT-JT, HRPT2, is located on 1q25-q31. 
5  Germline mutations of HRPT2 have been identified in more than half of 
HPT-JT families. 4-10  In addition, somatic mutations of HRPT2 were 
described in the majority of sporadic parathyroid carcinomas. 6,8,11  
  FIHP is a diagnosis of exclusion, and may be due to incomplete expression 
of a syndrome or to other clinical entities.  Germline mutations of MEN1, 12-15 
HRPT2, 6,16,17 and CASR 3,18 genes were reported in a small group of FIHP 
families; however, mutations in the 5’-regulatory region or gross deletion of 
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HRPT2 have not been analyzed in FIHP families. 8,17,18  
  In this study, we investigated the involvement of the HRPT2, MEN1, and 





















Patients and Methods 
Families 
  Eleven provisional FIHP (A to D, G to M) families and 2 HPT-JT (E and F) 
families were studied (Table 1).  Data of biochemical examination, magnetic 
resonance (MR) or computed tomography (CT) scan of the pituitary and 
pancreas regions, and no cutaneous lesions such as lipomas and angiofibromas 
did not support the diagnosis of MEN1 in all FIHP families and HPT-JT 
families (Table 1).  Physical examination revealed no jaw tumors in all FIHP 
families.  In 8 of 11 families, absence of jaw tumors was confirmed by 
orthopantomography or CT (Table 1).  The study was approved by our 
internal review board.  Fully informed consent was obtained in accordance 
with institutional guidelines.  The study was also conducted in accordance 
with the provisions of the Declaration of Helsinki.   
 
Family A 
  A proband (II-1 in Fig. 1) died of parathyroid carcinoma.  Sixteen years 
later, II-4 was found to have PHPT. 19  II-5 had an atypical parathyroid 
adenoma with cystic change.  Ten years after the surgery of II-4, III-3 was 
found to have right urolithiasis and hydronephrosis.  III-3 was found to have 
PHPT.  The pathological diagnosis of parathyroid adenoma was made from a 




  The proband (III-1) was found to have PHPT during hospitalization for the 
treatment of a left femoral fracture.  A left-inferior parathyroid adenoma was 
resected.  After the surgical operation, serum levels of calcium and PTH were 
within the normal range.  Nine years after the initial operation, PHPT recurred.     
The resected right-inferior gland was diagnosed with adenoma with cystic 
change, while 2 other resected glands were normal.  The paternal grandmother 
had multiple neck surgeries suggesting a possibility of parathyroidectomies, 
but her medical records could not be retrieved.  Information on his father was 
not available.  
 
Families C and D 
  In family C, the proband (I-1) was diagnosed with PHPT, which was also 
found in his daughter (II-1) and son (II-2).  The diagnosis of parathyroid 
tumors in I-1 was carcinoma. 20  I-1 underwent repeated resection of 
metastatic tumors in the mediastinum; however, serum levels of calcium and 
PTH were elevated.  In family D, a resected right-inferior parathyroid tumor 
of the proband (I-1) showed slight atypia and several capsular invasions, not 
vascular invasion. 21  Seven years later, the parathyroid tumor with lymph 
node metastasis was diagnosed as parathyroid carcinoma.  Six months after 
the second surgery, he underwent en bloc resection of the tumor and trachea.  
He died of local recurrence of parathyroid carcinoma.  Screening of family 
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members revealed that his son (II-1) had PHPT.   
 
Family E    
  Four resected tumors of the proband (II-2) showed parathyroid hyperplasia.  
One year later, a cementifying fibroma in the left mandible was resected. 22  
Her nephew (III-5) underwent total parathyroidectomy with transplantation.  
The parathyroid tumors in II-2 and III-5 did not have cystic features.  The 
remaining 7 family members did not have PHPT, jaw tumors, or cystic kidney 
lesions.  From these clinical data, the family was diagnosed as an HPT-JT 
family.   
 
Family F    
  The proband (II-1 in Fig. 2) had noticed swelling of the right maxilla for 3 
years, but its size had not changed.  When he visited the family dentist for the 
treatment of caries, complete evaluation of the tumor was recommended.  
Biochemical screening revealed hypercalcemia.  Subsequent CT of the neck 
suggested a left-superior parathyroid tumor.  US did not show cysts or tumors 
in the kidney.  A jaw tumor and a parathyroid tumor were resected and 
diagnosed as cement-ossifying fibroma and adenoma, respectively. 23  The 
parathyroid adenoma did not have cystic features.  His younger sister 
underwent surgical operation due to Wilms’ tumor at the age of 1.  His 
parents and the younger sister showed normal levels of serum PTH and calcium.  
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From these clinical data, the patient was diagnosed with sporadic HPT-JT.   
 
Families G to M 
  Clinical data on families G to M were shown in Table 1.  In family M, II-1 
and II-2 showed slightly elevated serum levels of gastrin, however, pancreatic 
tumors were not detected by CT scan. 24  The hypergastrinemia might have 
been due to gastric achlorhydria.  
 
Preparation of DNA and RNA 
  Genomic DNA was isolated from leukocytes and parathyroid tumors by 
standard proteinase K-sodium dodecyl sulfate digestion and the 
phenol/chloroform method.  Total RNA from tumors was prepared with 
ISOGEN (Nippon Gene, Tokyo, Japan).   
 
Gene nucleotide sequence analysis 
  We searched for HRPT2 mutations of by sequencing the entire coding region.  
The 17 coding exons of HRPT2 were amplified as 16 different fragments with 
primers derived from the flanking intronic or untranslated regions.  
Furthermore, nucleotide sequences of the 5’ regulatory region spanning 528 bp 
from the translation initiation site of HRPT2 were analyzed.  Somatic 
mutations of HRPT2 in DNA from parathyroid tumors were analyzed.  In 
addition, nucleotide sequencing of the coding region and exon-intron junctions 
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of the MEN1 and CASR genes was analyzed.  Primer sequences for the 
screening of HRPT2, MEN1, and CASR genes are available on request.  PCR 
products were subjected to direct sequencing using an ABI PRISM BigDyeTM 
terminators v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA) 
and analyzed on an ABI PRISM 3100 analyzer (Applied Biosystems). 
 
Microsatellite analysis and loss of heterozygosity (LOH) analysis 
  Intragenic microsatellite markers located on introns 10 and 14 11 in HRPT2 
were evaluated in DNA from leukocytes (families A to M) and from 5 
parathyroid tumors (family A).  Electrophoresis of 6-FAM-labeled products 
on an Applied Biosystems 3730xl DNA Analyzer was followed by pattern 
analysis using GeneMapper Software v3.5 (Applied Biosystems).  LOH in 
parathyroid tumors was considered present when the signal intensity of one 
allele was reduced by more than 50% in comparison with the corresponding 
allele in normal DNA.  In addition, information by direct sequencing of 
intragenic HRPT2 polymorphisms and mutation was used for LOH analysis.  
 
RNA analysis in parathyroid tumors  
  cDNA was synthesized from total RNA with random hexamers.  cDNA 
was amplified with primers: 5’-GGGGAAGATGGCGGACGTGC-3’ and 
5’-GGTAGGTTCCCATAGTGTCAA-3’.  The PCR amplified a 953 bp 
fragment containing a part of exon 1 through to a part of exon 7 of the HRPT2 
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gene.  The PCR products were cloned into the pCR4 Blunt-TOPO vector with 
a Zero Blunt TOPO PCR Cloning Kit (Invitrogen Co., San Diego, CA).  Each 
clone was sequenced using a sequencing kit. 
 
Sodium bisulfite modification and bisulfite sequencing  
  Genomic DNA was modified by sodium bisulfite treatment and purified 
using a BisulFast Methylated DNA Detection Kit (TOYOBO, Osaka, Japan) 
according to the manufacturer’s recommendations.  The methylation status of 
the HRPT2 promoter region was determined by bisulfite genomic sequencing 
as previously described. 25  Bisulfite-treated DNA was amplified with primers: 
5’-TGTTGGGGATGGAAGTGTTGATTTATT -3’ and 
5’-ACAATCTCCTTCTTCTAAATATTATACTAT-3’.  PCR products of 564 
bp in size were cloned into the pCR4 Blunt-TOPO vector (Invitrogen Co.).  
Five clones each were sequenced using a sequencing kit. 
 
Results   
Nucleotide sequence analysis of HRPT2, MEN1, and CASR at the germline 
level 
  An HRPT2 germline mutation of 518-521del was found in affected members 
of family A (II-3, II-4, II-5, and III-3) (Table 1 and Fig. 1).  The mutation was 
not detected in an unaffected family member (II-6) or 50 normal Japanese 
individuals.  An HRPT2 germline mutation of 62-66del was detected in a 
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member of family B (Table 1).  In a patient with PHPT and a jaw tumor (II-1 
in Fig. 2), a germline mutation of 39delC was detected.  The mutations of 
518-521del, 62-66del, and 39delC resulted in a frameshift, leading to a 
premature stop codon.   
  In family F, the germline mutation of 39delC was not detected in his 
unaffected parents or his younger sister.  Direct sequencing in exon 1 showed 
that the proband (II-1 in Fig. 2) and the proband’s father (I-1 in Fig. 2) had a 
heterozygous nucleotide change of G to T at -10.  Heterozygosity of G and T 
at -10 was detected in 1 subject among 50 normal Japanese individuals, 
suggesting a single nucleotide polymorphism (SNP).  Subcloning and 
sequencing of PCR products in II-1 showed that clones with T at -10 and 
39delC, and clones with G at -10 and wild type at 39 were separately obtained.  
Haplotype analysis in family F showed that the 39delC mutation is located on 
the paternal haplotype (Fig. 2), suggesting that the mutation occurred de novo 
in the father’s spermatogenesis.  
  Although known polymorphisms of NCBI reference SNP ID number 
rs10737631 (A/C) in the 5’ regulatory region and IVS2 + 28T/C/del4 were 
found, no mutations in HRPT2 were identified in an HPT-JT family or in 9 
other FIHP families (Table 1).  Mutational analysis of MEN1 showed a 
mutation of G225R (GGA to AGA) in family M.  We further addressed 
germline mutations of CASR, however, none could be demonstrated (Table 1).  
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Nucleotide sequence analysis of HRPT2 at the somatic level 
  HRPT2 screening in genomic DNA from 5 parathyroid tumors revealed that 
2 adenomas had somatic mutations of 70-73del (an adenoma, II-4 in Fig. 1) and 
95-102del (an atypical adenoma, II-5 in Fig. 1).  Subcloning and sequencing 
of reverse transcription (RT)-PCR products showed that somatic mutations 
were located in the residual allele to the allele having the germline mutation.  
In an adenoma from II-4, we identified 10 clones.  Among them, 2 clones 
contained only 518-521del and 7 clones contained only 70-73del.  One clone 
contained a normal nucleotide sequence.  In an atypical adenoma from II-5, 4 
clones contained only 518-521del, and 3 clones contained only 95-102del 
among 8 clones selected.  One clone contained a normal nucleotide sequence.	 	
In an atypical adenoma (II-4) and two adenomas (II-5 and III-3), somatic 
mutations in HRPT2 were not detected. 
 
LOH analysis in parathyroid tumors 
  Germline DNAs of patients in family A were heterozygous for at least one 
microsatellite marker of intron 10 or 14.  Five tumors retained heterozygosity 
at the HRPT2 locus.  Results by direct sequencing of rs10737631, 
IVS2+28T/C/del4 or 518-521del in tumor DNA confirmed the retention of 
heterozygosity.  
 
Methylation status of HRPT2 promoter in parathyroid tumors  
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  We analyzed the methylation status of the promoter region including 65 CpG 
sites in 5 parathyroid tumors and 4 corresponding leukocytes (Family A). 	







































  We previously described family A as FIHP because of the following 
findings: 1) absence of jaw tumor and kidney lesions and 2) lack of LOH at 1q. 
19  The majority of parathyroid tumors in HPT-JT patients are aggressive, 
occasionally recurrent adenomas, notable also for their cystic histology. 26  
The development of 1 parathyroid carcinoma and 2 atypical adenomas 
suggested the possibility of HPT-JT in family A.  518del4 mutation was 
detected in patients with PHPT and a healthy mother (I-2 in Fig. 1) with normal 
serum levels of calcium and PTH.  Nearly 10% to over 30% of mutation 
carriers of HPT-JT appear to remain clinically inert in adulthood. 3-4  This 
contrasts markedly with MEN1, which has an age-related penetrance of more 
than 98% by the age of 40. 27  A precise estimate of the age-related penetrance 
of HRPT2 mutation requires information from a large number of families.   
	 LOH at 1q24-q32 was identified in some, but not all HPT-JT-associated 
parathyroid tumors, suggestive of a tumor suppressor role for HRPT2. 28,29   
Five parathyroid tumors in family A were negative for LOH at the HRPT2 
locus.  The presence of somatic mutations on the residual allele to the 
germline mutation in 2 parathyroid tumors directly shows that the biallelic 
inactivation of HRPT2 is associated with the disease.  In parathyroid tumors 
with germline mutations of HRPT2, a second hit was observed in 7 of 12 
tumors: LOH at HRPT2 in 3 tumors and somatic mutations in 4 tumors. 6,10,11  
LOH at HRPT2 in HPT-JT-associated parathyroid tumors are not as frequent as 
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LOH at MEN1 in MEN1-associated parathyroid tumors. 30,31  Transcriptional 
inactivation by hypermethylation of CpG islands containing gene promoter 
regions is one of the main mechanisms of tumor suppressor gene inactivation 
in tumors 32; however, methylated CpG sites in the HRPT2 promoter were not 
found in 5 parathyroid tumors from family A.  The results suggested that 
promoter hypermethylation of HRPT2 did not contribute to inactivation of the 
residual alleles.  The mechanism of tumorigenesis in tumors without LOH or 
somatic mutations of HRPT2 remains to be elucidated. 
  In family B, the proband with parathyroid adenoma with cystic change was 
considered to have sporadic parathyroid adenomas.  Several patients with 
sporadic parathyroid carcinoma were found to have germline mutations of 
HRPT2, 6,8,11 suggesting an occult form of HPT-JT.  Whether his grandmother 
had PHPT or not remains unclear; however, the identification of HRPT2 
mutation confirms that he can be classified as having HPT-JT.  Our two 
families A and B as well as those reported by others 4,5,7,8,17 lacked the typical 
clinical manifestations of HPT-JT.  From these results, genetic testing for 
HRPT2 will be taken into consideration in FIHP families with parathyroid 
carcinomas, atypical adenomas, or cystic adenoma. 
  Although the father-derived de novo mutation of RET is a common 
phenomenon in MEN2B, 33 the de novo mutation of HRPT2 has been reported 
in only one HPT-JT family showing mosaicism for L64P. 17  Haplotype 
analysis showed that the de novo mutation in family F was derived from the 
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father.  The development of Wilms’ tumor in 3 HPT-JT patients suggested 
that it might be a component of HPT-JT 34,35, however, the absence of HRPT2 
mutation in the younger sister with Wilms’ tumor showed that Wilms’ tumor 
was not a component of HPT-JT in family F. 
  The development of parathyroid carcinoma in FIHP families suggested 
HPT-JT; however, HRPT2 mutations were not detected in families C and D.  
In addition, no germline mutations of HRPT2 were detected in the remaining 7 
FIHP families (families G to M).  Although family E was diagnosed with 
HPT-JT based on clinical grounds, no germline mutations of HRPT2 were 
detected.  Indeed, Carpten et al. 5 reported that HRPT2 sequencing fails to 
identify a mutation in about half of index patients from families with a full 
expression of HPT-JT and with proven genetic linkage to 1q24-q32.  
Mutations of the 5’-regulatory region of HRPT2, which have not been analyzed 
in other reports, were negative.  So-far-unidentified mutations may also 
represent gross deletions or rearrangements in HRPT2 that cannot be readily 
identified using direct sequencing; however, the retention of heterozygosity of 
polymorphic markers in families C to E (Table 1) suggested that the possibility 
of gross deletion of one allele, which was shown at the MEN1 locus, 36,37 
spanning the entire HRPT2 gene was low.  It is possible that other tumor 
suppressor genes may contribute to the development of parathyroid tumors in 
FIHP. 
  Missense MEN1 mutation of G225R in family M was consistent with the 
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other report that FIHP families predominantly have missense mutations of 
MEN1. 14  The average percentage of MEN1 mutations in FIHP families was 
reported to be 18%. 15  Lower frequency of MEN1 mutations in our study 
might be due to exclusion of 2 families previously shown to carry MEN1 
mutations. 
  In conclusion, 2 families diagnosed with provisional FIHP were found to 
carry HRPT2 germline mutations, and a father-derived de novo HRPT2 
germline mutation was found in a patient with HPT-JT.  Our results confirm 
the need for testing for HRPT2 in FIHP families, especially those with 
parathyroid carcinomas, atypical adenomas, or adenoma with cystic change.  
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Figure 1.  Pedigree of family A.  Family members are indicated by 
generation (Roman numerals) and individuals (Arabic numerals).  Individuals 
are represented as male (squares) and female (circles).  The proband is 
indicated by an arrow.  Closed symbols denote affected members.  Open 
symbols denote unaffected members.  Asterisks denote unaffected individuals 
confirmed by biochemical study and CT scan/orthopantomography.  
Sequencing of HRPT2 showed a wild-type sequence (wt) or the presence of a 
mutation (mut).  nd: germline mutations of HRPT2 were not analyzed.  
 
Figure 2.  Paternal origin of de novo mutation of HRPT2 in the family F.  
Genotypes in the HRPT2 gene are shown for NCBI reference SNP ID number 
rs10737631 in the 5’ regulatory region (rs10737631), a newly identified SNP at 
-10 from the translation initiation site (-10), an identified germline mutation 
(39delC) at 39 (39), a SNP at IVS2+28 (IVS2+28), a micosatellite marker in 
intron 10 (intron 10), and a micosatellite marker in intron 14 (intron 14).  Wt 
denotes a normal sequence.  The pedigree symbols are as described in Fig. 1. 
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